Keyword: Regeneron Pharmaceuticals
Strong data for Dupixent in sinusitis could boost sales for Sanofi and Regeneron, but challenges abound, including payer pushback.
Sanofi and Regeneron's Libtayo may be the sixth in its class to launch, but it already has something not all its rivals do: a market all to itself.
Xolair, Nucala, Cinqair, Fasenra and Dupixent will need to take a 50% to 68% discount off the list price to achieve cost-effectiveness, says ICER.
The new eczema data came a month ahead of an expected FDA decision on the drug's fate in asthma.
Regeneron is supersizing a campus expansion in New York, investing $800 million and adding 1,500 jobs.
Sanofi and Regeneron are ready to wheel and deal if they win the FDA's blessing to tout their cholesterol drug Praluent's cardiovascular benefits.
Only days after the FDA turned away Regeneron's Eylea for a label expansion, the drugmaker has secured the approval it sought.
What does severe eczema feel like? Sanofi and Regeneron's first Dupixent ads feature images—tiny crawling insects, for one—to illustrate just that.
The FDA has issued a CRL for Regeneron's application to extend the dosing schedule for blockbuster Eylea from eight to 12 weeks.
Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.